Details for Patent: 5,716,644
✉ Email this page to a colleague
| Title: | Composition for sustained release of non-aggregated erythropoietin |
| Abstract: | A composition, and methods of forming and using said composition, for the sustained release of non-aggregated, biologically active, erythropoietin (EPO). The sustained release composition of this invention comprises a polymeric matrix of a biocompatible polymer and particles of biologically active, aggregation-stabilized EPO, wherein said particles are dispersed within the biocompatible polymer. The method of the invention for producing a composition for the sustained release of biologically active EPO, includes dissolving a biocompatible polymer in a polymer solvent to form a polymer solution, dispersing particles of biologically active, aggregation-stabilized EPO in the polymer solution, and then solidifying the polymer to form a polymeric matrix containing a dispersion of said EPO particles. The method for using a composition of the invention is a method for providing a therapeutically effective blood level of biologically active, non-aggregated erythropoietin in a subject for a sustained period. In this method, a subject is administered an effective dose of the sustained release composition of the present invention. |
| Inventor(s): | Zale; Stephen E. (Hopkington, MA), Burke; Paul A. (Medford, MA), Bernstein; Howard (Cambridge, MA), Brickner; Avram (Brookline, MA) |
| Assignee: | Alkermes, Inc. (Cambridge, MA) |
| Filing Date: | Jun 07, 1995 |
| Application Number: | 08/478,502 |
| Claims: | 1. Biologically active, aggregation-stabilized erythropoietin, comprising a lyophilized solution containing: a) biologically active erythropoietin; b) ammonium sulfate; and c) a buffer with a pH between 5 and 7. 2. A method for forming particles of biologically active, aggregation-stabilized erythropoietin, comprising the steps of: a) mixing ammonium sulfate with a solution of isolated biologically active erythropoietin to form an aggregation stabilizing mixture; b) forming particles from said mixture, wherein said particles contain isolated biologically active erythropoietin and ammonium sulfate. 3. A method for providing a therapeutically effective blood level of biologically active, non-aggregated erythropoietin in a subject for a sustained period, comprising administering to the subject a dose of a composition for the sustained release of biologically active, non-aggregated erythropoietin from a polymeric matrix, comprising: a) a biodegradable polymer; and b) particles of biologically active, aggregation-stabilized erythropoietin, wherein said particles include erythropoietin in contact with ammonium sulfate and wherein said erythropoietin particles are dispersed within the polymeric matrix. 4. A method for providing a therapeutically effective blood level of biologically active, non-aggregated erythropoietin in a subject for a sustained period, comprising administering to the subject a dose of a composition for the sustained release of biologically active, non-aggregated erythropoietin from a polymeric matrix, comprising: a) a biodegradable polymer; and b) particles of biologically active, aggregation-stabilized erythropoietin, wherein said particles include erythropoietin in contact with ammonium sulfate and are formed by lyophilizing a mixture containing: a) biologically active erythropoietin; b) ammonium sulfate; and c) a buffer with a pH between about 4 and about 8; and wherein said erythropoietin particles are dispersed within the polymeric matrix. |
